Patents by Inventor Koen De Witte

Koen De Witte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
    Patent number: 12178805
    Abstract: The present provides compounds and methods for preventing and/or treating epilepsy and/or neurodegenerative disorders. More particularly, the invention provides inhibitors of PDE6? for use in the prevention and/or treatment of neurodegenerative disorders and/or epilepsy.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 31, 2024
    Assignees: ReMYND N.V., Katholieke Universiteit Leuven
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom François L. Van Dooren, Koen De Witte
  • INHIBITORS OF PDE6DELTA FOR USE IN THE PREVENTION AND/OR TREATMENT OF EPILEPSY AND/OR NEURODEGENERATIVE DISORDERS
    Publication number: 20200253934
    Abstract: The present provides compounds and methods for preventing and/or treating epilepsy and/or neurodegenerative disorders. More particularly, the invention provides inhibitors of PDE6? for use in the prevention and/or treatment of neurodegenerative disorders and/or epilepsy.
    Type: Application
    Filed: May 11, 2018
    Publication date: August 13, 2020
    Inventors: Johan Gerard Griffioen, Katrien Princen, Tom François L. Van Dooren, Koen De Witte
  • OXADIAZOLE COMPOUNDS
    Publication number: 20200140400
    Abstract: The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1, R2, R3, L1, L2, L3, L4, L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, an protein misfolding disorders.
    Type: Application
    Filed: January 2, 2020
    Publication date: May 7, 2020
    Applicant: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Matthias Nettekoven, Mark Rogers-Evans
  • Oxadiazole compounds
    Patent number: 10562869
    Abstract: The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1, R2, R3, L1, L2, L3, L4, L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: February 18, 2020
    Assignee: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Matthias Nettekoven, Mark Rogers-Evans
  • 2,7-diazaspiro[3.5]nonane compounds
    Patent number: 9750745
    Abstract: The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R1, R3, R4, L1, L2, L3, L4, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: September 5, 2017
    Assignee: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Mark Rogers-Evans
  • 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS
    Publication number: 20170157137
    Abstract: The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R1, R3, R4, L1, L2, L3, L4, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Applicant: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Mark Rogers-Evans
  • 2,7-diazaspiro[3.5]nonane compounds
    Patent number: 9617264
    Abstract: The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R1, R3, R4, L1, L2, L3, L4, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 11, 2017
    Assignee: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Mark Rogers-Evans
  • 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS
    Publication number: 20170015665
    Abstract: The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R1, R3, R4, L1, L2, L3, L4, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Application
    Filed: March 17, 2015
    Publication date: January 19, 2017
    Applicant: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Mark Rogers-Evans